Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Paris  >  PCAS    PCA   FR0000053514

PCAS (PCA)
Mes dernières consult.
Most popular
Delayed Quote. Delayed  - 07/21 05:35:19 pm
17 EUR   +1.01%
07/19 PCAS : sustained growth in net sales
07/05 NOMBRE TOTAL DE : Juin 2017
07/03 PCAS : ex-dividend day for final dividend
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

PCAS : quarterly financial reporting Sep 30, 2011

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/07/2011 | 05:40pm CEST

Quarterly financial reporting
As of 30 September 2011

 

 

Business update

 

(in thousands of euros)20112010% change
 First Quarter44,05341,4346,3%
 including Pharmaceutical Synthesis27,14726,6032,0%
 including Specialty Chemicals16,90614,83114,0%
 Second Quarter41,78942,698-2,1%
 including Pharmaceutical Synthesis26,45728,100-5,8%
 including Specialty Chemicals15,33214,5985,0%
 Third Quarter33,48133,658-0,5%
 including Pharmaceutical Synthesis19,53018,3946,2%
 including Specialty Chemicals13,95115,264-8,6%
 Total as of 30 September119,323117,7901,3%
 including Pharmaceutical Synthesis73,13473,0970,1%
 including Specialty Chemicals46,18944,6933,3%

 

 

 

The PCAS Group's consolidated revenues at 30 September 2011came in 1.3% higher than the same period the previous year.

 

Pharmaceutical Synthesis
Over the first five months of the year, business was affected by the planned reduction in the contribution by the new contract between PCAS and Sanofi, effective since 31 May 2010. Excluding this contract, the Exclusive and Non-Exclusive Pharma business is up 10.5% at 30 September 2011.
Fine Specialty Chemicals
With growth of 3.3% at 30 September 2011, the Fine Specialty Chemicals business contracted by 8.6% during the third quarter of 2011 in relation to 2010, reflecting the economic slowdown seen since the summer.

 

Key operations and events for the quarter

 

No important events likely to have a significant impact on the company's business or situation occurred during the third quarter of 2011.

 

Outlook for the current year

 

The high level of sales expected for the fourth quarter should lead to earnings growth in 2011.

 

 

Next date :  2011 earnings, February 22nd, 2012

 

 

About PCAS
PCAS is a fine and specialty chemicals group that shares an ambition for excellence with its customers, which primarily include market-leading international groups. PCAS designs and delivers the best industrial solutions for its customers' specific expectations. These various expectations all share a common demand for safety, quality, competitiveness, innovation and sustainability.

 

Longjumeau, October 7th, 2011

 

PCAS_T3_2011_EN:
http://hugin.info/143512/R/1553112/478624.pdf



This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.

Source: PCAS via Thomson Reuters ONE

HUG#1553112
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on PCAS
07/19 PCAS : sustained growth in net sales
07/05 NOMBRE TOTAL DE DROITS DE VOTE ET D' : Juin 2017
07/03 PCAS : ex-dividend day for final dividend
06/06 NOMBRE TOTAL DE DROITS DE VOTE ET D' : Mai 2017
05/18 PCAS : Document de référence 2016
05/16 PCAS : Annual Report 2016 PCAS
05/15 PCAS : Sustained growth in Net sales
05/15 PCAS : Project of strategic combination between Novacap and PCAS
03/22 PCAS : 2016 Annual Results
02/21 PCAS : 2016 Annual Results
More news
Financials (€)
Sales 2017 208 M
EBIT 2017 19,2 M
Net income 2017 10,6 M
Debt 2017 45,9 M
Yield 2017 1,33%
P/E ratio 2017 22,17
P/E ratio 2018 18,15
EV / Sales 2017 1,46x
EV / Sales 2018 1,36x
Capitalization 257 M
Chart PCAS
Duration : Period :
PCAS Technical Analysis Chart | PCA | FR0000053514 | 4-Traders
Technical analysis trends PCAS
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 2
Average target price 17,0 €
Spread / Average Target -0,18%
EPS Revisions
Managers
NameTitle
Vincent Touraille CEO & Financial Communications Contact
Christian Moretti Chairman
Pierre Schreiner Chief Operating Officer
Eric Moissenot Deputy CEO-Finance & Administration
Gérard Guillamot Director-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
PCAS21.26%300
JOHNSON & JOHNSON17.45%364 503
ROCHE HOLDING LTD.4.90%221 492
NOVARTIS8.37%220 936
PFIZER3.08%199 378
MERCK AND COMPANY6.39%171 303